What is watchful waiting and is it appropriate for my Prostate Cancer

Watchful Waiting vs. Active Surveillance for Prostate Cancer

I want to help clarify an important distinction here, because the terminology matters for your care decisions.

Understanding the Terms

Watchful Waiting and Active Surveillance are often used interchangeably, but they're actually different approaches:

• Active Surveillance = Regular monitoring with the intent to treat if the cancer shows signs of becoming more aggressive
• Watchful Waiting = Monitoring primarily for symptom management, typically when treatment isn't planned

For prostate cancer, Active Surveillance is the preferred approach when appropriate, according to current medical practice.

When Active Surveillance May Be Appropriate

Based on the CancerPatientLab webinars on prostate cancer management, active surveillance is generally considered for patients with:

Lower-risk disease characteristics:

• Gleason score of 6 (the least aggressive grade) - though even this requires careful evaluation
• Stable PSA (prostate-specific antigen, a blood marker) after initial diagnosis
• No evidence of metastases (cancer spread beyond the prostate)
• Longer PSA doubling time (greater than 15 months) - meaning your PSA is rising slowly, if at all

According to the webinars, if your "Time to BCR" (biochemical recurrence) is greater than 3 years AND your PSA doubling time is greater than 15 months, active surveillance of your recurrence may be appropriate.

The Clinical Reasoning

Here's how oncologists think about this decision:

Why active surveillance can work:

• Some prostate cancers grow very slowly and may never cause serious harm during a patient's lifetime
• Avoiding immediate treatment means avoiding side effects like incontinence, erectile dysfunction, and hormone therapy complications
• You preserve treatment options for later if the cancer shows signs of becoming more aggressive
• Your quality of life may be better in the short term

Why it requires careful monitoring:

• You need regular PSA blood tests to track if levels are rising
• Imaging studies (like PSMA PET scans) may be needed to check for spread
• Biopsies might be repeated to confirm the cancer hasn't changed to a more aggressive grade
• The moment your cancer shows signs of progression, treatment becomes necessary

Important Questions to Ask Your Doctor

To determine if active surveillance is right for YOUR specific situation:

1. What is my Gleason score, and what does that tell us about my cancer's aggressiveness?
2. What is my current PSA level, and what is my PSA doubling time? (How fast is it rising?)
3. Do I have any evidence of metastases on imaging? (Has the cancer spread?)
4. What specific monitoring schedule would you recommend? (How often PSA tests, imaging, biopsies?)
5. What are the warning signs that would mean we need to start treatment? (What changes would trigger a shift in strategy?)

The Reality Check

As noted in the CancerPatientLab webinars, there's an important psychological aspect: Many patients struggle with the idea of "doing nothing" when told they have cancer. Even when active surveillance is medically appropriate, some patients feel anxious about waiting. This is completely normal, and it's worth discussing with your care team.

The webinars also emphasize that your prognosis depends heavily on your specific cancer characteristics - not just the diagnosis alone. Two patients with "prostate cancer" can have very different outlooks based on their Gleason score, PSA level, and whether the cancer has spread.

What You Should Do Next

1. Get comprehensive testing - Ensure you have genetic testing (DNA/RNA sequencing) and imaging like PSMA PET scans to fully characterize your cancer
2. Understand YOUR numbers - Know your Gleason score, PSA level, PSA doubling time, and staging
3. Discuss monitoring plans - If active surveillance is recommended, get clear details on how often you'll be tested and what triggers treatment
4. Consider a second opinion - Especially from a medical oncologist experienced in prostate cancer, not just a urologist

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.